BioSpace News Archive

Alentis Therapeutics announced the FDA cleared an IND application for ALE.C04 as a monotherapy and in combination with pembrolizumab, in a first-in-human clinical trial in recurrent or metastatic Head and Neck Squamous Cell Carcinoma that is expected to start during the second half of 2023.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced Company management will participate in the following investor conferences.

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, announced that it will be honored during Premier, Inc.'s annual supplier Innovation Celebration at the 2023 Breakthroughs Conference and Exhibition.

Apyx Medical Corporation announced it has received 510 clearance from the U.S. Food and Drug Administration for the Renuvion Micro Handpiece, a new addition to the Renuvion product family.

Motus GI Holdings, Inc. announced that the Pure-Vu Gen 4 Gastro and Colon system was featured during the 9th Ecuadorian Institute of Digestive Diseases Live Endoscopy Course 2023 at the Pentax Learning Center, which is considered one of the most important digestive medicine annual events held in the Latin American region with over 1,000 physicians registered.

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced that Company CEO, Dan Goldberger, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, being held June 20 – 22, 2023.

MediWound Ltd. announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest.

Onconova Therapeutics, Inc. presented preclinical data on narazaciclib at the 17th International Conference on Malignant Lymphoma, which is taking place in Lugano, Switzerland, through June 17, 2023.

Cue Biopharma, Inc. announced that it will deliver an oral presentation on its Immuno-STAT™ platform and biologics as well as a poster on the company’s bispecific protein, CUE-401, for the treatment of autoimmune and inflammatory diseases at the Federation of Clinical Immunology Societies 2023 Annual Meeting, being held June 20-23, 2023 in Boston, Massachusetts.